21 Jan 2026 | 5 Mins Read
Zydus bids to buy Ardelyx for $2.5 billion
Flipitmoney
Zydus Lifesciences is reportedly exploring a $2.2-2.5 billion acquisition of US-based biopharmaceutical company Ardelyx Inc. The deal would be funded through a Rs 5,000-crore equity raise and internal cash reserves. Ardelyx focuses on first-in-class drugs for gastrointestinal and cardio-renal diseases with $378 million in revenue in 2025, up 18% year-on-year.